Nissan Versa

Kelley Blue Book Analysis: Average New-Vehicle Transaction Prices Up Less Than 1% Year Over Year, Smallest Increase in Decade

Retrieved on: 
Wednesday, August 9, 2023

Compared to the start of the year, transaction prices are down 2.7%, or $1,335, the largest January to July tumble in the past decade.

Key Points: 
  • Compared to the start of the year, transaction prices are down 2.7%, or $1,335, the largest January to July tumble in the past decade.
  • "New-vehicle prices, primarily driven by cuts in luxury and electric vehicles, are decreasing as inventory is steadily improving.
  • According to Kelley Blue Book estimates, the lower prices at Tesla are likely helping with sales volume.
  • For comparison, Kelley Blue Book estimates incentives averaged 5.9% of ATP in July 2021 and 10.3% in July 2019.

Toyota Crown Wins Green Car Journal's Prestigious 2023 Green Car of the Year®, Additional Green Car Awards™ Winners Revealed

Retrieved on: 
Tuesday, November 8, 2022

LOS ANGELES, Nov. 8, 2022 /PRNewswire/ -- Toyota's all-new Crown sedan has been named Green Car Journal's 2023 Green Car of the Year, earning the most coveted environmental award in the automotive field.

Key Points: 
  • LOS ANGELES, Nov. 8, 2022 /PRNewswire/ -- Toyota's all-new Crown sedan has been named Green Car Journal's 2023 Green Car of the Year, earning the most coveted environmental award in the automotive field.
  • "Complementing Green Car of the Year are winners in eight Green Car Awards categories that show how widespread environmental achievement is across the spectrum of today's advanced vehicle lineups."
  • All finalists considered in a Green Car Awards category stand out with their commendable environmental achievement and are awarded Green Car Journal's 2023 Green Car Product of Excellence.
  • Green Car Awards are presented by Green Car Journal , an industry-leading publication since its launch in 1992.

Deal or no deal? FTC challenges yo-yo financing tactics

Retrieved on: 
Sunday, November 6, 2022

Although the dealer may be the creditor, it doesnt usually service the financing contract and instead looks to assign it to a bank, credit union, or finance company.

Key Points: 
  • Although the dealer may be the creditor, it doesnt usually service the financing contract and instead looks to assign it to a bank, credit union, or finance company.
  • Rather than handling the financing themselves or returning the consumers down payment and trade-in, some unscrupulous dealers use deceptive or unfair tactics to pressure consumers into a different deal so the dealer doesnt lose the sale.
  • According to the FTC complaint against Sage Auto Group and affiliates, thats what happened to some people doing business with the defendants.
  • The dealer would sign a contract with a consumer that included financing terms and then let the person drive off the lot.
  • But if the dealer couldnt (or didnt) assign the financing contract, in some instances it wouldnt just cancel the transaction.
  • Youll want to read the complaint for the details of the defendants alleged yo-yo financing practices and why the FTC is challenging them as deceptive and unfair.
  • The FTC says dealers falsely told some consumers that the add-ons were required or would improve their chances of getting financing.
  • Additional counts challenge what the headline giveth, the footnote taketh away tactics the FTC has alleged as deceptive in numerous other cases.
  • And only in the fine print did the ad disclose that the deal was for a lease, not a purchase.

Gravity Branding names Novartis’ Vijoice® (alpelisib)

Retrieved on: 
Monday, August 8, 2022

SAN FRANCISCO, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Gravity Branding, the agency behind naming blockbuster drugs including Novartis Kisqali (ribociclib), Genentechs Herceptin (trastuzumab) and Janssens Concerta (methylphenidate HCl), recently announced its success naming Vijoice (alpelisib), a Novartis drug to combat PIK3CA-Related Overgrowth Spectrum (PROS).

Key Points: 
  • SAN FRANCISCO, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Gravity Branding, the agency behind naming blockbuster drugs including Novartis Kisqali (ribociclib), Genentechs Herceptin (trastuzumab) and Janssens Concerta (methylphenidate HCl), recently announced its success naming Vijoice (alpelisib), a Novartis drug to combat PIK3CA-Related Overgrowth Spectrum (PROS).
  • Weve enjoyed a highly collaborative, productive working relationship with the Novartis team over many years on a wide range of projects, said Edward Saenz, Managing Director, Gravity Branding.
  • For naming Vijoice, as with other initiatives, we employed our proven Brand Bullseye process, which helps teams align around a singular expression of brand value.
  • In addition to Gravitys pharmaceutical naming experience, the agency works alongside Novartis and its technology partners on branding ground-breaking digital therapeutics.

Autotrader Reports 20 New Vehicles Consistently Selling Over Sticker Price

Retrieved on: 
Monday, August 30, 2021

ATP is a measure of the selling price in a deal versus the Manufacturer's Suggested Retail Price (MSRP).

Key Points: 
  • ATP is a measure of the selling price in a deal versus the Manufacturer's Suggested Retail Price (MSRP).
  • The vehicles listed also have very low incentives, which usually is a sign that the vehicle is in high demand.
  • For more information and advice from Autotrader on vehicle supply and related pricing, visit https://www.autotrader.com/car-news/these-vehicles-are-selling-for-over-... .
  • Cox Automotive Inc. makes buying, selling, owning and using vehicles easier for everyone.